Infinium Pharmachem share price
NSE: INFINIUMPharmaceuticals & Biotechnology
Last close ₹286.00down ₹10.50 (3.54%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹296.50.
52-week range of traded prices to 23 Oct 2026
₹189.40Low, 30 Mar 2026₹324.50High, 6 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹446 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 29 May 2026
- 36.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 3.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 29 May 2026
- 10.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day.
- 4,000
Results
Consolidated; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 29 May
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹106 Crup 25.62%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹6.55 Crup 16.94%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 6.2%
Revenue by year
Peak revenue ₹190 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025Filed 29 May | Sep 2025Filed 18 Nov | Mar 2026Filed 29 May |
|---|---|---|---|---|---|---|
| Revenue | 61 | 74 | 83 | 73 | 84 | 106 |
| Net profit | 6 | 5 | 5 | 4 | 6 | 7 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 10.2% | 6.9% | 5.8% | 5.1% | 6.7% | 6.2% |
Consolidated. The 7 half years from Mar 2023, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. No results on record for the half year to Mar 2023.
Business segments
In the year to Mar 2026 the company reports one business segment, Single segment, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, EV/EBITDA: a period of the last twelve months does not state its operating profit. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 68% of 238 trading days over the last year.
LowestHighest
Its median35.3Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 90% of 238 trading days over the last year.
LowestHighest
Its median2.9Industry median2.8
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −20.3% | +49.2% | −46.6% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Infinium Pharmachem in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 TranschemTRANSCHEM | 513 | 76.2 | 6.1 | – | −100.0% | +47.5% | 8.3% | −4.9% | 0.00% |
 KRM AyurvedaKRMAYURVED | 508 | – | 4.4 | – | – | – | – | – | 0.00% |
 Trident LifelineTLL | 488 | 23.2 | 4.9 | – | – | – | 25.5% | – | 0.00% |
 Haleos LabsHALEOSLABS | 453 | 28.7 | 2.1 | 13.7 | −3.1% | −8.5% | 7.7% | 7.4% | 0.10% |
 Albert DavidALBERTDAVD | 436 | 19.3 | 1.1 | 16.1 | +11.4% | +258.5% | 5.8% | 4.1% | 0.65% |
 Jenburkt PharmaceuticalsJENBURPH | 384 | 11.7 | 2.0 | 8.1 | +9.1% | +1.2% | 17.8% | 19.2% | 2.38% |
 Medicamen BiotechMEDICAMEQ | 344 | – | 1.2 | 18.5 | +24.7% | – | – | 3.7% | 0.39% |
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 340 | – | – | – | −7.7% | – | – | 1.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
22 Sep · Rating
Infinium Pharmachem share price by year
Each calendar year to 2025.Infinium Pharmachem share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 222.90 | −25.7% | 325.35 | 215.00 |
| 2024 | 299.90 | +27.6% | 386.80 | 183.05 |
| 2023 | 235.00 | – | 314.45 | 73.90 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 17 Apr 2023.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 303.50 | 303.50 | 284.00 | 286.00 | 291.81 | 4,000 | – |
| 22 Oct 2026 | 303.75 | 303.75 | 282.85 | 296.50 | 286.69 | 4,500 | 100.0% |
| 21 Oct 2026 | 303.50 | 303.50 | 281.00 | 297.70 | 290.80 | 2,000 | 100.0% |
| 19 Oct 2026 | 307.80 | 307.80 | 292.25 | 294.90 | 299.07 | 4,000 | 62.5% |
| 16 Oct 2026 | 319.50 | 319.50 | 302.00 | 305.05 | 304.40 | 5,000 | 100.0% |
| 15 Oct 2026 | 300.00 | 317.00 | 300.00 | 313.60 | 314.29 | 25,500 | 92.2% |
| 14 Oct 2026 | 302.00 | 302.00 | 302.00 | 302.00 | 302.00 | 500 | 100.0% |
| 13 Oct 2026 | 312.00 | 312.00 | 302.00 | 302.00 | 304.43 | 3,500 | 100.0% |
| 12 Oct 2026 | 324.50 | 324.50 | 317.00 | 317.00 | 320.75 | 1,000 | 100.0% |
| 9 Oct 2026 | 321.00 | 321.00 | 302.10 | 312.50 | 311.27 | 3,000 | 100.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 13 Sep 2023 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- Legal name
- Infinium Pharmachem Limited
- NSE symbol
- INFINIUM
- ISIN
- INE0MRE01011
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Apr 2023
- Face value
- ₹10